Literature DB >> 7813387

Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat.

S Hirano1, K Wakazono, N Agata, H Iguchi, H Tone.   

Abstract

The authors have examined the cardiotoxic actions of pirarubicin (THP), compared with epirubicin (EPI) and doxorubicin (DXR), on the electrocardiogram (ECG) and myocardial structure in rats. The rats were treated once a week for four weeks with DXR (total dose 10 mg/kg), and then further treated (post-treated) once a week for four weeks with THP, EPI or DXR (total dose 5 and 10 mg/kg). In the ECG study, a prolongation of QaT interval (interval from the upstroke of R wave to the apex of T wave) and a flattening of T wave were observed more severely in the rats post-treated with EPI and DXR than in those treated with THP. Also, a prolongation of QRS duration was observed more prominently in those treated with DXR than with THP and EPI. Histopathologically, a vacuolization and swelling of myocardial cells and an infiltration of mononuclear cells were observed more severely in the rats post-treated with EPI and DXR than in those treated with THP. Furthermore, a meandering of myofibril was observed in those treated with EPI and DXR, but not with THP. These results suggest that the cardiotoxic actions of THP are weaker than those of EPI and DXR and that the replacement of DXR with THP leads to more successful cancer chemotherapy with less cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7813387

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  8 in total

1.  Epidermal growth factor receptor/heme oxygenase-1 axis is involved in chemoresistance to cisplatin and pirarubicin in HepG2 cell lines and hepatoblastoma specimens.

Authors:  Takashi Kobayashi; Masayuki Kubota; Yoshiaki Kinoshita; Yuki Arai; Toshiyuki Oyama; Naoki Yokota; Koichi Saito; Yasunobu Matsuda; Mami Osawa
Journal:  Pediatr Surg Int       Date:  2019-09-26       Impact factor: 1.827

2.  Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study.

Authors:  Hiroki Hori; Tooru Kudoh; Shinichiro Nishimura; Megumi Oda; Makoto Yoshida; Junichi Hara; Akio Tawa; Ikuya Usami; Akihiko Tanizawa; Keiko Yumura-Yagi; Koji Kato; Ryoji Kobayashi; Yoshihiro Komada; Keitaro Matsuo; Keizo Horibe
Journal:  Int J Clin Oncol       Date:  2016-11-17       Impact factor: 3.402

3.  Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?

Authors:  Wenxi Yu; Lina Tang; Feng Lin; Yang Yao; Zan Shen
Journal:  Med Oncol       Date:  2014-11-29       Impact factor: 3.064

Review 4.  Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review.

Authors:  Erik Hefti; Javier G Blanco
Journal:  Cardiovasc Toxicol       Date:  2016-01       Impact factor: 3.231

5.  Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

6.  The role of nitric oxide in Doxorubicin-induced cardiotoxicity: experimental study.

Authors:  Ayşenur Bahadır; Nilgün Kurucu; Mine Kadıoğlu; Engin Yenilme
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

7.  Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments.

Authors:  Esperanza Herradón; Cristina González; José A Uranga; Raquel Abalo; Ma I Martín; Visitacion López-Miranda
Journal:  Front Pharmacol       Date:  2017-05-08       Impact factor: 5.810

8.  MicroRNA-129-1-3p protects cardiomyocytes from pirarubicin-induced apoptosis by down-regulating the GRIN2D-mediated Ca2+ signalling pathway.

Authors:  Qi Li; Meng Qin; Qi Tan; Tengteng Li; Zehui Gu; Peng Huang; Liqun Ren
Journal:  J Cell Mol Med       Date:  2020-01-19       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.